CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH The recall affects Albuterol Sulfate Inhalation Aerosol, 90mcg, specifically batches manufactured in November 2021.
Pharmaceutical company Cipla has initiated a recall of six specific batches of Albuterol Sulfate Inhalation Aerosol due to a defect in the container. This decision was reached after the discovery of a leakage through the inhaler valve in one of the batches. The aerosol is vital for the treatment of acute asthma exacerbations, and the defect could lead to life-threatening consequences, although no adverse events have been reported thus far.
Key Points:
- Six batches have been recalled, with batch numbers including IB20045, IB20055, IB20056, IB20057, IB20059, and IB20072, all expiring in November 2023.
- A leakage was observed in one inhaler in batch number IB20056, leading to the recall from an abundance of caution.
- The defect may prevent the recommended dose from being delivered, potentially resulting in serious consequences.
Additional Points:
- Replacement inhalers should be obtained by consumers from the affected batches.
- Adverse events can be reported to the FDA’s MedWatch program.
- Further information is available through Cipla’s customer service via phone or email.
Conclusion:
- This recall serves as a precautionary measure to prevent any potential harm that might arise from the container defect, and prompt action is required to ensure patient safety.
Allergy & Immunology Latest Posts
- COVID Spike Proteins Help Cancer Cells Survive, Resist Chemotherapy: Brown University Preprint Paper
- Modified RNA in COVID Vaccines May Contribute to Cancer Development: Review
- Evolution of Pyoderma Gangrenosum
- Vaccinated People Are Immune Imprinted, Have Unusual Response to COVID-19 mRNA Boosters
- FDA Grants Emergency Use of Pemgarda for Preexposure Prophylaxis of COVID-19
Did You Know?
According to the World Health Organization, asthma affects approximately 339 million people globally and causes around 417,000 deaths annually.
